SCH772984

目录号:S7101

SCH772984 Chemical Structure

Molecular Weight(MW): 587.67

SCH772984是一种新型特异性的ERK1/2抑制剂,无细胞试验中IC50分别为4 nM和1 nM, 对含有RAS或BRAF突变的癌细胞具有强大的功效。

规格 价格 库存 购买数量  
RMB 2210.07 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的4个实验数据:

  • 293T cells were transfected with Flag-WT-FBW7. Thirty hours post transfection, cells were pretreated with MG132 and various MEK/ERK inhibitors overnight before harvesting. FBW7 phosphorylation status was examined by immunoblot analysis after immunoprecipitation.

    Cell Research, 2015, 25: 561-573. SCH772984 purchased from Selleck.

    Int J Oncol, 2018, 53(2):750-760. SCH772984 purchased from Selleck.

  • K562 cells were exposed to ERK inhibitor SCH772984 (1 uM, 2 uM, 5 uM) for 48 h. Apoptosis was analyzed by Annexin V-APC labeling.

    Leuk Lymphoma 2014 1, 8. SCH772984 purchased from Selleck.

    ERK1/2 influences the effects of TGF-β1 on Cdk5 and Bax in PC12 cells. A. Original western blot showing the level of Cdk5 and respective Actin in PC12 cells with TGF-β1 (40 ng/ml) treatment in the presence of SCH772984(1 μM) and LY294002(1.5 μM) for 2 h. B. Arithmetic means ± SEM (n = 4) of Cdk5 protein abundance in PC12 cells with TGF-β1 treatment in the presence of SCH772984(1 μM) and LY294002(1.5 μM) for 2 h. C. Original western blot showing the level of Bax and respective Actin in PC12 cells with TGF-β1 (40 ng/ml) treatment in the presence of SCH772984(1 μM) for 2 h. D. Arithmetic means ± SEM (n = 4) of Bax protein abundance in PC12 cells with TGF-β1 treatment in the presence of SCH772984(1 μM) for 2 h. **(p < 0.01), ***(p < 0.001) indicate statistically significant difference.

    Biochem Biophys Res Commun, 2017, 485(4):775-781. SCH772984 purchased from Selleck.

产品安全说明书

ERK抑制剂选择性比较

生物活性

产品描述 SCH772984是一种新型特异性的ERK1/2抑制剂,无细胞试验中IC50分别为4 nM和1 nM, 对含有RAS或BRAF突变的癌细胞具有强大的功效。
特性 SCH772984不直接抑制MEK1, MEK2, BRAF, 或 CRAF酶活性。
靶点
ERK2 [1]
(Cell-free assay)
ERK1 [1]
(Cell-free assay)
1 nM 4 nM
体外研究

SCH772984是新型,选择性,ATP竞争性的ERK1/2抑制剂。SCH772984抑制ERK底物p90核糖体S6激酶(T359/S363 磷酸化-RSK)的磷酸化,这种作用存在剂量依赖性。SCH772984也能抑制ERK自身活化环中残基的磷酸化。SCH772984分别抑制约88%和49%BRAF突变型或RAS-突变型肿瘤细胞系,EC50值<500 nM。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
2P-ERK2 MmTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnxemNKSzVyPUCuNlQhdk1? M{XkXFI2OzVyOUOx
WM-266-4 NGfJVm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTJyIH7N NW\ZZnV5OjN4MUS4PVg>
UACC-62 Mmr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnmTWM2OD1|MDDuUS=> NEnOUoEzOzZzNEi5PC=>
Colo-205 NITWbI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTN4IH7N M2CyZ|I{PjF2OEm4
SK-Mel-1 M122Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDQb3FKSzVyPUO3JI5O M{jsZVI{PjF2OEm4
WiDr NF3lSldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDu[5lKSzVyPUO5JI5O MUWyN|YyPDh7OB?=
M14 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFm0N3NKSzVyPUS3JI5O NFrNdmUzOzZzNEi5PC=>
HT-29 M3\LXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rNWmlEPTB;NUCgcm0> M{ezPVI{PjF2OEm4
8505C NWD3TYZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDBTWM2OD13MDDuUS=> NHzlO2gzOzZzNEi5PC=>
HT-144 M{fkeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\hUGlEPTB;NkCgcm0> MV6yN|YyPDh7OB?=
SK-Mel-5 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33udmlEPTB;Nk[gcm0> NV7XRoIyOjN4MUS4PVg>
A375-SM NYLPWlB2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml33TWM2OD15NTDuUS=> NWHERmdyOjN4MUS4PVg>
SK-Mel-28 M1rkS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LVOGlEPTB;OEWgcm0> NFj4fnAzOzZzNEi5PC=>
LOX NWf4SlRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH36eJRKSzVyPUGwNEBvVQ>? MnrSNlM3OTR6OUi=
SK-Mel-3 Mn:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HON2lEPTB;MUG4JI5O NY\rW2R1OjN4MUS4PVg>
K1 Mm\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn73TWM2OD1zM{Cgcm0> M1HLOFI{PjF2OEm4
Hs-695T NFHO[HFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvqNYVKSzVyPUG2OUBvVQ>? NFm1XHkzOzZzNEi5PC=>
BHT-101 NHrKcndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3ETWM2OD1|MECgcm0> NFz3dlAzOzZzNEi5PC=>
RPMI-7951 NVnTXphOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2C2fGlEPTB;M{S0JI5O M1vxUFI{PjF2OEm4
A2058 NEW4NZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTN4MDDuUS=> NVm0bZpyOjN4MUS4PVg>
SK-Hep-1 M{HzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTF2MkKgcm0> NFvpNJUzOzZzNEi5PC=>
A673 NHvxe3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVniS3l5UUN3ME2zNFAyKG6P NGC0flIzOzZzNEi5PC=>
DBTRG-05MG NUTZPGQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\aNWlEPTB;M{CwNUBvVQ>? NVywXYFiOjN4MUS4PVg>
SW-626 M2\ae2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTN|IH7N M3jaWVI{PjF2OEm4
LoVo M4S0fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnMUnVDUUN3ME20O{BvVQ>? MoDQNlM3OTR6OUi=
MiaPaCa NFvrSFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;iXmlEPTB;NUOgcm0> M4SxNVI{PjF2OEm4
SW-620 M4raTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTFyNDDuUS=> NHPqNZUzOzZzNEi5PC=>
CAPAN-1 NXTB[nltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX64UmRHUUN3ME2xNFQhdk1? M2\rNVI{PjF2OEm4
SW-527 MoDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4[0TGlEPTB;MUKxJI5O MY[yN|YyPDh7OB?=
HCT-116 NYPjXZhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jDSWlEPTB;MUK4JI5O NWnrPFlqOjN4MUS4PVg>
SW-480 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\XclRKSzVyPUG2OUBvVQ>? MYGyN|YyPDh7OB?=
HPAC NGfve5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2i1dGlEPTB;MUewJI5O NYLLZYxVOjN4MUS4PVg>
OVCAR-5 MkXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\EVG56UUN3ME2yNFghdk1? NVLLVpBIOjN4MUS4PVg>
AsPc-1 M4\Nd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorTTWM2OD1{N{Cgcm0> MWOyN|YyPDh7OB?=
A549 Ml;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLPPXNKSzVyPUOyOkBvVQ>? NUe4O5E2OjN4MUS4PVg>
SNU-1 MmfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTN3NDDuUS=> M2LYclI{PjF2OEm4
HOP62 NYHZ[pVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3kfnFKSzVyPU[3OkBvVQ>? MWWyN|YyPDh7OB?=
H23 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vGcWlEPTB;MUCwNEBvVQ>? NUi5VJppOjN4MUS4PVg>
MB-231 Ml;2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LDTmlEPTB;MUCwNEBvVQ>? NF7oVZAzOzZzNEi5PC=>
SU.86.86 NXr2fXNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\3ToRZUUN3ME2xNFAyKG6P NFrRe4EzOzZzNEi5PC=>
CFPAC-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nHdGlEPTB;MUCwNUBvVQ>? NVTGcZJHOjN4MUS4PVg>
A427 MnnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlq3TWM2OD1zNEOzJI5O MWGyN|YyPDh7OB?=
MDAH-2774 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTJ4NUegcm0> NYT4Xmg6OjN4MUS4PVg>
NCI-H157 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HTZWlEPTB;M{CwNEBvVQ>? NEDDeWQzOzZzNEi5PC=>
HTB-177 NVPjPVllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTNyMECgcm0> MojiNlM3OTR6OUi=
UM-UC-3 M{fzTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3BTWM2OD1|MECxJI5O NFPVfpAzOzZzNEi5PC=>
HCT-8 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTNyMEGgcm0> NVLoS2R7OjN4MUS4PVg>
Panc-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTNyMEGgcm0> MVeyN|YyPDh7OB?=
DLD-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLjTWM2OD1|MECxJI5O NWPRN3VsOjN4MUS4PVg>
HCT-15 M1;UPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTNyMEGgcm0> MWGyN|YyPDh7OB?=
HL-60 M1e5Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoK4TWM2OD1|MDDuUS=> MkHDNlM3OTR6OUi=
SK-Mel-2 M{XiXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjlTWM2OD1|NDDuUS=> M1r5UFI{PjF2OEm4
RD MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DEbGlEPTB;MUKzJI5O MmLqNlM3OTR6OUi=
HT-1197 MnHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmW5TWM2OD1|MU[gcm0> NH6yeVUzOzZzNEi5PC=>
Molt-3 NEjFZXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mof6TWM2OD14MECgcm0> M3rlU|I{PjF2OEm4
PA-1 M3LZ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTFyMEGgcm0> MYmyN|YyPDh7OB?=
Molt-4 NYLCb4FyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;1SHFKSzVyPUOwNFEhdk1? NFz2NlQzOzZzNEi5PC=>
NCI-H292 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnr6TWM2OD17MDDuUS=> NHv3VIwzOzZzNEi5PC=>
A2780 NX34dXVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInne49KSzVyPUG0N{BvVQ>? NV[5SGFQOjN4MUS4PVg>
IGROV-1 NIj2ZplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrOV4JKSzVyPUG0OkBvVQ>? NWjnS5huOjN4MUS4PVg>
SK-N-SH NVrySmh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;QTWM2OD1zNUCgcm0> MWqyN|YyPDh7OB?=
N-87 M1n4dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIm3dIFKSzVyPUOwO{BvVQ>? MlnBNlM3OTR6OUi=
H322 NVO4bG1rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzKTWM2OD1|MkWgcm0> MojhNlM3OTR6OUi=
H716 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXMTWM2OD1|M{Sgcm0> M4ToelI{PjF2OEm4
TT MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXxW4ZiUUN3ME20NFYhdk1? NF[xPVQzOzZzNEi5PC=>
Caki-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\1fW93UUN3ME20OVAhdk1? NIi1VZIzOzZzNEi5PC=>
5637 NXXHVW85T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTZzMDDuUS=> M121T|I{PjF2OEm4
MB-453 NWCyZ3JQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1foSmlEPTB;NkeyJI5O MWeyN|YyPDh7OB?=
RT-4 NULvWGt{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPhcmlSUUN3ME24NVAhdk1? MV:yN|YyPDh7OB?=
HOP92 NYXablY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTh{MDDuUS=> Mnq1NlM3OTR6OUi=
KG-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInqeYZKSzVyPUmwNEBvVQ>? NYfvN3BpOjN4MUS4PVg>
Hs-294T M4TLUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{CxZmlEPTB;OUS1JI5O M3q4RVI{PjF2OEm4
SF-539 Mke0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vNU2lEPTB;MUCwNEBvVQ>? M4nMO|I{PjF2OEm4
U-251 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfYVoxTUUN3ME2xNFAxKG6P NVnydnBkOjN4MUS4PVg>
MB-468 NFTZb5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\ub|J2UUN3ME2xNFAxKG6P MoDhNlM3OTR6OUi=
HS746T MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2T3VGlEPTB;MUCwNEBvVQ>? NYHISIRPOjN4MUS4PVg>
SCABER MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vjbWlEPTB;MUCwNEBvVQ>? NXr5dHYxOjN4MUS4PVg>
MCF-7 NFPoe2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXH3[XpOUUN3ME2xNFAyKG6P M1fablI{PjF2OEm4
CHL-1 NYq2VopzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1i3cWlEPTB;MUS2NEBvVQ>? NHLueWwzOzZzNEi5PC=>
U87MG NWriRmo1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHxTWM2OD1{MECwJI5O MUmyN|YyPDh7OB?=
SJCRH30 Ml3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFGzdWFKSzVyPUKwNFIhdk1? NHm2NYszOzZzNEi5PC=>
ES-2 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml[wTWM2OD1{NkW5JI5O MWmyN|YyPDh7OB?=
HT-1376 NELPS41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvmdJJxUUN3ME2yPFAxKG6P NXfy[XQ{OjN4MUS4PVg>
A172 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PmfWlEPTB;M{CwNEBvVQ>? NVLMVHd[OjN4MUS4PVg>
769P MonWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTVXopKSzVyPUOwNFAhdk1? MnrqNlM3OTR6OUi=
NCI-H520 M1riSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTNyMECgcm0> MV[yN|YyPDh7OB?=
DU145 M{XVS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYr6WFl{UUN3ME2zNFAxKG6P M{DMRlI{PjF2OEm4
K562 NFnmdnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW[4TW43UUN3ME2zNFAxKG6P MXGyN|YyPDh7OB?=
U-937 NYfvVY9[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDGd|VRUUN3ME2zNFAxKG6P MmezNlM3OTR6OUi=
A204 NHnWNo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnflTWM2OD1|MECxJI5O NIDScm0zOzZzNEi5PC=>
DAOY NFLHbIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXXTWM2OD1|MECxJI5O M2DCcFI{PjF2OEm4
SF-268 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTNyMEGgcm0> M3jE[FI{PjF2OEm4
SF-295 NH\LRYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTNyMEGgcm0> Mn\nNlM3OTR6OUi=
SNB-19 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nTOGlEPTB;M{CwNUBvVQ>? NVTOTWx6OjN4MUS4PVg>
SNB-75 NW\5[HRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\p[YZsUUN3ME2zNFAyKG6P MVqyN|YyPDh7OB?=
U373-MG MkPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTNyMEGgcm0> NGe3XpkzOzZzNEi5PC=>
786-O MnyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mof2TWM2OD1|MECxJI5O NEnTT24zOzZzNEi5PC=>
A498 M1HBemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoL4TWM2OD1|MECxJI5O NX3LfJd6OjN4MUS4PVg>
ACHN NWn1eFdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTNyMEGgcm0> MWGyN|YyPDh7OB?=
EKVX NX;nUHRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVq0NFFbUUN3ME2zNFAyKG6P MYCyN|YyPDh7OB?=
H226 M4TY[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\NZm5KSzVyPUOwNFEhdk1? M3KwPFI{PjF2OEm4
H522 MnLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rW[mlEPTB;M{CwNUBvVQ>? M2XzOFI{PjF2OEm4
HeLa NH;sZopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTNyMEGgcm0> Ml7XNlM3OTR6OUi=
SK-OV-3 M2fBSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPD[JRKSzVyPUOwNFEhdk1? NXriTIZqOjN4MUS4PVg>
Ln Cap MlPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HQZmlEPTB;M{CwNUBvVQ>? M1rye|I{PjF2OEm4
PC3 M{iwfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NID2U2JKSzVyPUOwNFEhdk1? MXeyN|YyPDh7OB?=
SNU-16 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;OTm1WUUN3ME2zNFAyKG6P NG\nTXEzOzZzNEi5PC=>
FTC-133 NWCxWGhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\PbJp[UUN3ME2zNFAyKG6P M2jRV|I{PjF2OEm4
Ro82-W-1 Mk\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHOzeJlKSzVyPUOwNFEhdk1? NYrnWJVlOjN4MUS4PVg>
Daudi M{LPV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTNyMEGgcm0> MYKyN|YyPDh7OB?=
Jijoye MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmi3TWM2OD1|MECxJI5O NEXmcXYzOzZzNEi5PC=>
Jurkat MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fTV2lEPTB;M{CwNUBvVQ>? MXKyN|YyPDh7OB?=
J-82 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXqfI1KSzVyPUOwNFEhdk1? M4fud|I{PjF2OEm4
TCC-SUP MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLye4MyUUN3ME2zNFAyKG6P MofUNlM3OTR6OUi=
BT-474 NV72[JhMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXUTWM2OD1|MECxJI5O NV\K[3E1OjN4MUS4PVg>
ZR-75-1 Ml;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mme2TWM2OD1|MECxJI5O MoTQNlM3OTR6OUi=

... Click to View More Cell Line Experimental Data

体内研究 SCH772984按耐受剂量处理移植瘤模型,诱导肿瘤衰退。SCH772984作用于抗BRAF或MEK抑制剂的模型,有效抑制MAPK信号和细胞增殖。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

+ 展开

ERK2 IMAP 酶实验:

SCH772984作用于纯化的ERK2或ERK1,按一式两份进行8点稀释曲线。酶添加到实验板中。与化合物温育,然后加入底物肽和ATP溶液中。384孔板中每孔加入14μl稀释的酶(每组反应含0.3ng活性ERK2)。实验板轻轻震荡混合试剂,然后在室温下温育45分钟。加入60μl of IMAP 结合溶液 (IMAP珠在1X结合缓冲液中按1:2200稀释)终止反应。实验板在室温下再温育0.5小时,使磷酸肽与IMAP珠完全结合。然后在 LJL分析仪上读数。
细胞实验:

[1]

+ 展开
  • Cell lines: BRAF突变型或 RAS突变型肿瘤系
  • Concentrations: ~10 μM
  • Incubation Time: 5 天
  • Method:

    在96孔板中进行细胞增殖实验,细胞按每孔 4,000个的密度接种。接种24小时后,使用DMSO处理细胞,9点IC50稀释 (0.001-10 μM) ,DMSO终浓度为1%。使用ViaLight发光试剂盒5天后,测定存活力。细胞系存活力检测中,使用SCH772984处理细胞4天,然后进行CellTiterGlo发光细胞活力检测。


    (Only for Reference)
动物实验:

[1]

+ 展开
  • Animal Models: 裸鼠
  • Formulation: --
  • Dosages: 12.5 mg/kg, 25 mg/kg, 50 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 14 mg/mL warmed (23.82 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+30% PEG 300+ddH2O
0.6mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 587.67
化学式

C33H33N9O2

CAS号 942183-80-4
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    I would like to inhibit Erk1/2 by treating the mice with the inhibitor. by what kind of administration way and at what concentration could it be done?

  • 回答:

    SCH772984 can be administrated by I.P. The dosages can be used as: 12.5 mg/kg, 25 mg/kg, 50 mg/kg. For more detail information please find the paper below: http://cancerdiscovery.aacrjournals.org/content/3/7/742.full

ERK Signaling Pathway Map

Tags: 购买SCH772984 | SCH772984供应商 | 采购SCH772984 | SCH772984价格 | SCH772984生产 | 订购SCH772984 | SCH772984代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID